HHBT — HH Biotechnology Holdings Co Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.3% | ||
| Return on Equity | 10.04% | ||
| Operating Margin | 45.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.11 | 7.35 | 7.69 | 7.99 | 7.99 | n/a | n/a | 1.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HH Biotechnology Holdings Company, formerly Great China International Holdings, Inc., is engaged in commercial and residential real estate investment, development, sales and/or management in the city of Shenyang, Liaoning Province, in the People’s Republic of China (PRC). The Company's business segments are Property for sale, and Rental income and Income of management fee of commercial buildings. The Company conducts all operations through its direct and indirect subsidiaries, which include Shenyang Maryland International Industry Company Limited and Silverstrand International Holdings Company Limited. It is focused primarily on real estate leasing, management and consulting activities in the city of Shenyang. The Company's leasing and management services are conducted primarily with respect to its real estate projects, which include President Building, Chenglong Garden and the Maryland Building. It also holds over 2,190 square meters of retail space in Qiyun New Village.
Directors
- Frank Jiang CHM (62)
- Sheng Jiang CEO
- Lirong Wang CFO (54)
- Liang Zou VOP
- Sasaki Koji VPR
- Kunpeng Yu VPR
- Shuang Li SEC
- Huang Ying DRC
- Yizhao Zhang IND (50)
- Last Annual
- December 31st, 2015
- Last Interim
- September 30th, 2016
- Incorporated
- December 4th, 1987
- Public Since
- July 23rd, 2012
- No. of Employees
- 117
- Sector
- Real Estate Operations
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 14,059,966
- Address
- C Site 25-26F Presidential Building, SHENYANG, 110003
- Web
- Phone
- +86 2422813888
- Auditors
- Kabani & Co., Inc.
Similar to HHBT
286 Lenox Partners LLC
Pink Sheets on Nasdaq
Advanced Oxygen Technologies
Pink Sheets on Nasdaq
Advanced Lighting Solutions
Pink Sheets on Nasdaq
Everhome Realty
Pink Sheets on Nasdaq
AmBase
Pink Sheets on Nasdaq
FAQ
As of Today at 19:10 UTC, shares in HH Biotechnology Holdings Co are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in HH Biotechnology Holdings Co last closed at $0.00 and the price had moved by -99.97% over the past 365 days. In terms of relative price strength the HH Biotechnology Holdings Co share price has underperformed the S&P500 Index by -99.98% over the past year.
There is no consensus recommendation for this security.
HH Biotechnology Holdings Co does not currently pay a dividend.
HH Biotechnology Holdings Co does not currently pay a dividend.
HH Biotechnology Holdings Co does not currently pay a dividend.
To buy shares in HH Biotechnology Holdings Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in HH Biotechnology Holdings Co had a market capitalisation of .
Here are the trading details for HH Biotechnology Holdings Co:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HHBT
Based on an overall assessment of its quality, value and momentum HH Biotechnology Holdings Co is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HH Biotechnology Holdings Co. Over the past six months, its share price has underperformed the S&P500 Index by -49.94%.
As of the last closing price of $0.00, shares in HH Biotechnology Holdings Co were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HH Biotechnology Holdings Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
HH Biotechnology Holdings Co's management team is headed by:
- Frank Jiang - CHM
- Sheng Jiang - CEO
- Lirong Wang - CFO
- Liang Zou - VOP
- Sasaki Koji - VPR
- Kunpeng Yu - VPR
- Shuang Li - SEC
- Huang Ying - DRC
- Yizhao Zhang - IND